28, Jul 2026
NTPC Posts Strong Q1 Performance, Profit Rises 12 pc on Operational Growth
New Delhi, July 28: Power sector major NTPC Ltd has reported a strong performance in the first quarter, with its profit rising 12 per cent, beating market expectations and reflecting steady growth in its core operations.
The company’s improved earnings were supported by consistent power generation, efficient operations, and continued demand for electricity across the country.
NTPC said the quarterly performance reflects its focus on strengthening India’s energy security while advancing investments in renewable energy, technology upgrades, and sustainable power solutions.
The company continues to expand its clean energy initiatives alongside its conventional power business to meet the country’s growing electricity requirements and support long-term energy transition goals.
Industry experts said the positive results highlight the resilience of the power sector and NTPC’s ability to maintain growth momentum amid changing market conditions.
The strong quarterly performance is expected to reinforce investor confidence and support NTPC’s future expansion plans as the company continues to play a key role in India’s evolving energy landscape.
- 0
- By Neel Achary
28, Jul 2026
Study: Casdatifan Demonstrates Durable Tumor Responses in Heavily Pretreated Patients with Advanced Kidney Cancer
MIAMI, July 28: A new multi-center clinical study is shedding light on a potential new approach for patients with advanced kidney cancer, offering measurable clinical responses alongside a clearer view into how the disease operates beneath the surface.
Findings from the ARC-20 phase 1 clinical trial show that casdatifan, an oral investigational therapy designed to inhibit hypoxia-inducible factor-2 alpha, produced durable tumor responses with a manageable safety profile in patients with heavily pretreated clear cell renal cell carcinoma, the most common form of kidney cancer. The study appears in Nature.
For a disease that often adapts and resists treatment, the results provide an early signal that a more targeted approach may help slow its momentum.
“These findings are encouraging and suggest we may be able to better understand which patients benefit from targeting this pathway,” said co-author of the study, Jamie Merchan, M.D., co-leader of the Translational and Clinical Oncology Research Program at Sylvester Comprehensive Cancer Center, part of University of Miami Miller School of Medicine, and director of its Phase 1 Clinical Trials Program.
Clear cell renal cell carcinoma is driven in large part by abnormal activation of HIF-2α, a transcription factor that helps tumors grow, spread and survive in low-oxygen environments.
In many ways, the pathway acts like a control center inside the tumor, switching on signals that fuel its growth. While earlier therapies have attempted to interrupt this process, response rates have remained limited in patients whose disease progresses after initial treatment.
Casdatifan was designed to more effectively interrupt that signal, with characteristics intended to improve how the drug reaches and engages tumor tissue.
The ARC-20 study enrolled 127 patients with advanced, treatment-resistant disease, most of whom had received multiple prior therapies. Among patients receiving the recommended dose, the confirmed objective response rate was 35%. Across the full study population, the response rate was 31%, with more than 80% of patients achieving disease control, including stable disease.
Responses occurred within a median of approximately three months. In some cases, tumors continued to shrink over time rather than plateau early.
“These results are notable in a heavily pretreated population,” said Merchan. “They suggest this approach may provide meaningful activity for patients who have limited options.”
The study was a single-arm, early-phase trial and was not designed to compare casdatifan directly with other therapies. Differences in study design and patient populations also limit cross-trial comparisons.
A defining feature of the study is how closely it connects what is happening in the clinic to what is happening inside the tumor. Researchers observed that reductions in serum erythropoietin, a marker regulated by HIF-2α, were associated with higher response rates, lower rates of disease progression and longer progression-free survival.
Tumor analyses reinforced the pattern. Patients whose tumors showed higher levels of HIF-2α-related activity were more likely to benefit, suggesting the drug is engaging the pathway it was designed to target. Together, these findings begin to map a clearer connection between tumor biology and treatment response, helping researchers see not just whether a therapy works, but why.
“This is an important step in understanding how tumor biology may help guide treatment decisions,” Merchan said.
The safety profile of casdatifan was consistent with other therapies targeting the same pathway. Common side effects included anemia, fatigue and hypoxia, most of which were managed with supportive care and dose adjustments. Treatment discontinuation related to the study drug was infrequent, and no treatment-related deaths were reported.
While the results are encouraging, researchers emphasize that additional studies are needed to better define the role of casdatifan in treating advanced kidney cancer. Ongoing clinical trials are evaluating the therapy in combination with other treatments to determine whether outcomes can be further improved.
Casdatifan remains investigational in this setting and is not yet part of standard treatment.
For now, the ARC-20 study offers a clearer glimpse into how targeting a central cancer pathway may influence outcomes, particularly in tumors that appear to depend on that signal.
“In a disease that can shift and adapt over time, even a clearer line of sight into its underlying biology represents meaningful progress, helping guide where research and treatment strategies move next,” Merchan.
28, Jul 2026
MEI Sector Set for Strong Salary Growth in FY27, Says Report
New Delhi, July 28: Salaries in the MEI (Manufacturing, Engineering and Infrastructure) sector are expected to grow by 9.4 per cent in FY27, reflecting positive business sentiment and continued demand for skilled professionals, according to a report.
The projected salary growth highlights the sector’s steady expansion, driven by increased investments, infrastructure development, and rising demand for specialised talent.
Industry experts said companies are focusing on attracting and retaining skilled employees as competition for experienced professionals continues to increase across key segments.
The report noted that the growth in compensation is expected to be supported by improving business activity, technological advancement, and the need for workforce capabilities in emerging areas.
The positive salary outlook indicates growing opportunities for professionals in the MEI sector and reflects the broader momentum in India’s industrial and infrastructure landscape.
28, Jul 2026
Zain Omantel International (ZOI) and Tata Communications Partner on a Next-Generation Roaming Platform
Muscat, Oman, July 28 – Zain Omantel International (ZOI), a global hyperscale networking provider, and Tata Communications, the leading global communications technology player, have entered into a Memorandum of Understanding (MoU) to collaborate on a next-generation inter-operator roaming platform. The collaboration will explore how blockchain technologies can be used to modernise the roaming lifecycle, from partner management and commercial agreements to reconciliation, settlement and dispute resolution.
Through this collaboration, ZOI and Tata Communications will assess a secure platform that uses data driven and machine-led capabilities to automate and simplify roaming operations, while blockchain provides a trusted, transparent and tamper-resistant record of commercial activity between operators.
Sohail Qadir, CEO at ZOI said, “International roaming services including voice calls, messaging and data remain critical to how people and businesses stay connected across borders. Our collaboration with Tata Communications is focused on streamlining international roaming through smarter infrastructure and simplified operating models. It is an opportunity to explore how intelligent automation and blockchain can enhance the roaming lifecycle and end-user experience.”
ZOI’s international roaming footprint covers nearly 700 networks worldwide, extending over 200 countries. It carries more than 10 billion international voice minutes a year. Tata Communications has over 600 mobile network operator (MNO) partners, connecting four out of five mobile subscribers globally.
“Mobile operators are looking to improve efficiency, accelerate settlement cycles and deliver a better roaming experience for customers,” said Vivek Manglik, Executive Vice President – Interaction Fabric at Tata Communications. “The industry has an opportunity to rethink how roaming relationships are managed, using technologies such as intelligent automation and blockchain to reduce complexity and increase transparency. Together with ZOI, we are exploring a platform that will help operators streamline operations, strengthen partner collaboration and unlock greater value from their roaming ecosystems.”
The collaboration reflects ZOI’s wider strategy to simplify international telecoms through trusted partnerships, intelligent infrastructure and customer-focused innovation. It also reinforces Tata Communications’ role in helping service providers modernise global mobility services and deliver better experiences for their customers.
28, Jul 2026
Young Indian Climber Amieyra Khoslla Shines on World Stage
New Delhi, July 28: Young Indian climber Amieyra Khoslla has achieved a remarkable milestone by setting a new national record at the World Youth Climbing Championships, bringing recognition to India on the international sporting stage.
The record-breaking performance reflects Khoslla’s dedication, determination, and years of hard work in the demanding sport of climbing. Her achievement has highlighted the growing presence of Indian athletes in global climbing competitions.
Khoslla’s success is being seen as an inspiration for young athletes across the country and a boost for the development of sport climbing in India.
With increasing participation, better training opportunities, and greater exposure to international events, Indian climbers are steadily making their mark worldwide.
Her achievement adds a proud chapter to India’s emerging sporting journey and showcases the potential of young talent in reaching new heights.
28, Jul 2026
New Hub & Spoke System Boosts Amritsar’s International Connectivity
Amritsar, July 28: Amritsar has become the second airport in India to join the government’s Hub & Spoke international connectivity framework, providing passengers access to more than 20 international destinations through Indian aviation hubs.
The initiative, launched by the Ministry of Civil Aviation, aims to make international travel easier for passengers from regional cities by connecting them with major hub airports.
Under the new system, travellers from Amritsar can complete check-in, immigration, and baggage formalities at the origin airport, ensuring a smoother transfer experience at the connecting hub.
Civil Aviation Minister Ram Mohan Naidu said the move will strengthen Amritsar’s role as a major international gateway for Punjab and neighbouring regions, benefiting tourists, businesses, and the Indian diaspora.
The government said the Hub & Spoke model will help boost tourism, trade, investment, and regional development while strengthening India’s position as a global aviation hub.
More regional airports are expected to be added to the network in phases, expanding seamless international connectivity across the country.
28, Jul 2026
Economist Enterprise research, supported by HCLTech, confirms confidence in AI is high for the Telecom, Media, Semiconductor and Technology (TMT) industry, but business impact is still limited
New York And Noida, India, July 28: HCLTech, a leading global technology company, today announced the release of a new research report conducted by Economist Enterprise, the business-to-business arm of The Economist Group providing media solutions and intelligence services to organizations. Supported by HCLTech, the report examines how AI is reshaping competitive boundaries across the telecommunications, media and technology (TMT) industries and the widening gap between executive optimism and measurable business impact.
Based on insights from more than 200 C-suite executives across telecom, media, technology and semiconductor organizations in the U.S. and Europe, the research reveals that AI is accelerating convergence across the TMT ecosystem, forcing companies to rethink traditional industry boundaries as competitors, partners, adjacent verticals converge to create new sources of growth, differentiation and value.
The research also highlights an AI value paradox: while 91% of organizations believe their AI investments are delivering results, only one-third can measure the business value created, raising a critical question: how can organizations unlock AI’s full potential if they cannot consistently quantify the value it generates?
The report further highlights an execution gap as organizations move from AI experimentation to scaled adoption. While talent upskilling ranks as the top future AI investment priority, only 20% of organizations currently have a strategy for AI upskilling or hiring within their AI initiatives. Additionally, despite rapid AI deployment, only 17% report that governance is actively shaping how their AI systems operate.
“Our research makes clear that industry leaders recognize how AI can unlock new revenue models, strengthen customer relationships and bring them closer to their end customers,” said Charlotte Bullard Davies, Principal, Research Methods & Innovation at Economist Enterprise. “Organizations that successfully combine strategic focus, ecosystem collaboration and disciplined governance will be best positioned for future business growth.”
“The boundaries that once separated TMT are rapidly dissolving as AI becomes embedded across every layer of the value chain,” said Anil Ganjoo, Chief Growth Officer, and Global Head of Telecom, Media and Technology at HCLTech. “The next era of growth and competitive advantage will belong to organizations that move beyond AI experimentation and adoption toward industrialization, leveraging AI investments to deliver measurable business impact, create differentiated experiences and unlock new sources of growth.”
28, Jul 2026
India Aims to Build Global Pharma Hub Through Innovation: Piyush Goyal
New Delhi, July 28: The government is committed to strengthening India’s pharmaceutical sector by promoting innovation, research, and global competitiveness, Union Commerce and Industry Minister Piyush Goyal said.
Goyal said the focus is on creating a strong ecosystem that supports pharmaceutical companies, encourages research and development, and helps Indian firms expand their presence in global markets.
He highlighted that India’s pharma industry plays a crucial role in providing affordable medicines worldwide and has become an important pillar of the country’s healthcare and economic growth.
The minister said continued investment, technological advancement, and collaboration between industry and stakeholders will help India build a stronger and more innovative pharmaceutical sector.
The government remains focused on making the pharma industry more competitive, sustainable, and globally recognised, he added.
28, Jul 2026
Preventive Care and HPV Vaccination Key to Ending Cervical Cancer
New Delhi, July 28: The HPV vaccine can play a significant role in preventing cervical cancer and reducing the global burden of the disease, an Indian-American radiation oncologist has said, underlining the importance of vaccination, early screening, and greater health awareness among women.
The oncologist said cervical cancer is among the most preventable forms of cancer, with a majority of cases linked to persistent infection with high-risk strains of the Human Papillomavirus (HPV). Expanding access to HPV vaccination and regular screening programmes can help identify risks at an early stage and save lives.
Highlighting the role of preventive healthcare, the expert said timely vaccination, routine medical check-ups, and awareness about cervical cancer symptoms are essential steps towards reducing the impact of the disease.
Health specialists noted that HPV vaccination provides the greatest protection when administered before exposure to the virus, particularly during adolescence. Along with vaccination, regular cervical screening remains a critical tool for detecting early abnormalities and improving treatment outcomes.
The latest health insights highlight the need to strengthen awareness campaigns and improve access to vaccination and screening facilities, especially in underserved communities.
Doctors said a comprehensive approach combining prevention, early detection, and advanced treatment options could bring the world closer to the goal of eliminating cervical cancer as a major public health challenge.
28, Jul 2026
TriNetX Appoints August Calhoun Chief Executive Officer
Jeff Margolis Resumes Chairman Role as Company Completes CEO Transition
CAMBRIDGE, Mass., July 27, 2026 /PRNewswire/ — TriNetX, The Global Truth Engine for Better Human Health™ and operator of the world’s leading federated health data network, today announced the appointment of August Calhoun as Chief Executive Officer, effective immediately. Jeff Margolis, who has led the Company as the Interim CEO and Executive Chairman since December 2024, will resume his role as Chairman and TriNetX Director.
Mr. Calhoun brings more than 25 years of leadership experience in healthcare data, technology, and services. He has held senior executive positions spanning operations, sales, account management, and strategy across the industry’s most impactful organizations including RLDatix, Optum Insight, Change Healthcare, and Siemens. In these roles, Mr. Calhoun built and scaled category leaders serving providers, payers, and life sciences clients globally.
“Over the past 13 years, TriNetX has built something unique: a global health data network trusted by leading healthcare systems and life sciences organizations to answer their most challenging research questions,” said Mr. Calhoun. “The TriNetX industry-leading network and unparalleled data quality position the Company extraordinarily well to expand its global reach, further enrich its data assets, and deliver actionable insights to diverse healthcare stakeholders. I am honored to lead TriNetX, The Global Truth Engine for Better Human Health™, and to advance the mission that defines us.”
“August is exactly the leader TriNetX needs at this stage of its evolution,” said Jeff Margolis, Chairman. “His track record of building and scaling high-performing organizations in healthcare technology, combined with his deep understanding of data analytics and services, makes him uniquely suited to propel TriNetX’s mission. I am proud of what the TriNetX team has accomplished during this transition and look forward to continuing to support August and the Company as Board Chairman.”
Joe Bress, Partner and Global Co-Head of Healthcare for Carlyle, TriNetX’s lead investor, added, “We are delighted to welcome August as TriNetX’s permanent CEO. We also thank Jeff for his exceptional leadership during the interim period, which featured landmark achievements for the organization: a strategic collaboration and investment with Regeneron, the asset acquisition of Zetta Genomics, and the growth of its LIVE network beyond 300 million patients. Jeff led the Company through multiple cross-functional change initiatives designed to support the next stage of growth, while preserving TriNetX’s core strengths: its mission orientation, careful stewardship of provider partner relationships, and commitment to the highest standards of scientific integrity.”
TriNetX’s global network now encompasses real-world data from more than 300 million patients across over 25 countries, supporting clinical research, trial design, and real-world evidence generation for life sciences companies, healthcare providers, and academic research institutions worldwide.
About TriNetX, LLC
TriNetX is the Global Truth Engine for Better Human Health™ that makes complex, real-world health data easy to use. Data is sourced directly from our growing global network of over 11,000 healthcare provider locations. TriNetX customers select the data source, types, and breadth of data they need; the data access methods they desire; and the types of software, human and machine intelligence they wish to apply – and combine these to solve their business objectives. Visit TriNetX at www.trinetx.com or follow TriNetX on LinkedIn to learn more.
Media Contact
TriNetX
Karen Tunks, Director of Content & Communication
Email: Karen.Tunks@TriNetX.com
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/trinetx-appoints-august-calhoun-chief-executive-officer-302834499.html
